(AOF) – Theradiag announces a net result of 853,000 euros in the first half, compared to a net loss of 56,000 euros a year ago. The in vitro diagnostics specialist posted a turnover up 7% to 6.7 million euros and an operating profit of 835,000 euros, with an operating margin of 12.5%. As of June 30, 2023, Theradiag’s net available cash amounted to 5.7 million euros, a level higher than the company’s business plan and increasing during the second quarter of 2023, compared to 6.4 million euros. euros as of December 31, 2022.
Theradiag attributes these good results in particular to the progression of products with higher margins in its turnover, including mainly the growth in the share of autoimmunity within IVD and in the share of sales of tests in within Theranostics. The company also cites the receipt of milestone payments from Quotient following the strategic partnership and the optimization of the management of operational expenses mainly due to the cessation of activities in the United States.
AOF – LEARN MORE
Learn more about the Pharmacy sector
Biotechs put to the test
These companies are suffering from a much less favorable economic cycle, which is reflected in particular by a drop in venture capital financing of start-ups. These companies are therefore obliged to carry out layoff plans. Added to this is a much more restrictive regulatory framework. First, in the United States, measures linked to the Inflation Reduction Act (IRA) could have a strong impact on the margins of stakeholders. Indeed, from 2026, the federal Medicare program will be able to renegotiate the price of drugs marketed for nine years (chemical) or 13 years (biological), with discounts that could range from 35 to 60% for biotechs. Likewise, in Europe, with the new drug regulations presented in Brussels in April, the duration of patent protection will be reduced if the innovative treatment is not marketed in all member countries within two years.